Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.73 |
| ▸ | AKT1 | P31749 | 1/20 | 0.73 |
| ▸ | ABL1 | P00519 | 7/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | PRKACA | P17612 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | CSK | P41240 | 1/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.58 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.58 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.58 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.58 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1961935 | 0.86 | SRC (0.62) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL1318810 | 0.86 | SRC (0.79) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL30429079 | 0.85 | SRC (0.78) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL30175068 | 0.85 | SRC (0.78) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL12436052 | 0.85 | SRC (0.78) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL13019704 | 0.84 | SRC (0.76) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL13019850 | 0.84 | SRC (1.00) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL12436150 | 0.84 | AKT1 (1.00) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL409449 | 0.84 | SRC (0.76) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL12436053 | 0.84 | SRC (0.76) | SRCAKT1ABL1RIPK2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-4119552-A1 | REGULATING CHIMERIC ANTIGEN RECEPTORS | Dana-Farber Cancer Institute, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| US-11311609-B2 | Regulating chimeric antigen receptors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | SRC 3905/4885AKT1 4596/4885ABL1 2538/4885 |
| US-11311609-B2 | Regulating chimeric antigen receptors | NFATC1, TNFRSF9, IL2RA | SRC 303/4885AKT1 1695/4885ABL1 2453/4885 |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | SRC 1332/4885AKT1 968/4885ABL1 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.